{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020539","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.299990+00:00","generated_at":"2026-06-15T07:06:10.060560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rani Therapeutics Q1 net loss $16.8M; Celltrion partnership and FDA feedback on RT-102","bullets":["Net loss of $16.8M for Q1 2023, up from $13.8M in Q1 2022; non-cash stock compensation $4.0M.","Cash and equivalents $86.8M as of Mar 31, 2023; expected to fund operations to mid-2024.","Announced partnership with Celltrion to develop RT-111, an oral ustekinumab biosimilar.","FDA preliminary feedback supports 505(b)(2) pathway for RT-102 (osteoporosis); Phase 2 expected 2H 2023.","Three Phase 1 studies expected in 2023: RT-111, RT-105 (adalimumab biosimilar), RT-110 (parathyroid hormone)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020539","json":"https://secwatch.observer/filing/0000950170-23-020539.json","markdown":"https://secwatch.observer/filing/0000950170-23-020539.md","text":"https://secwatch.observer/filing/0000950170-23-020539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023020539/0000950170-23-020539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023020539/rani-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:06:10.060560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"11b206b2104a5dd47d70e763f2c7f1360bd39f0c","claim":"Rani Therapeutics Holdings, Inc. reported the three months ended March 31, 2023 results: net income $16.8 million.","evidence_excerpt":"Net loss for the three months ended March 31, 2023 was $16.8 million, compared to $13.8 million for the same period in 2022, including non-cash charges primarily attributable to stock-based compensation expense of $4.0 million for the three months ended March 31, 2023, compared to $3.0 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023020539/0000950170-23-020539-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"$16.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}